Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Corvus Pharmaceuticals, Inc.
Study ID
NCT04280328
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Ciforadenant — DRUG
    100 mg orally twice daily for 28-day cycles
  • daratumumab — DRUG
    16 mg/kg administered intravenously as follows based on 28-day cycles: * Cycles 1 - 2: Days 1, 8, 15, and 22 * Cycles 3 - 6: Days 1 and 15 * Cycles 7 - 24: Day 1

Study Details

This is a Phase 1b open-label study of ciforadenant, an oral, small molecule inhibitor targeting adenosine-2A receptors (A2AR), on safety/tolerability and efficacy in combination with daratumumab, a monoclonal antibody targeting CD38, in relapsed or refractory multiple myeloma.

Key Dates

Start date
Feb 20, 2020
Status verified
Mar 2022
Primary completion
Sep 21, 2021
Completion
Mar 1, 2022

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ciforadenant in combination with daratumumab
    Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg.

Primary Outcome Measure

Safety and tolerability of ciforadenant in combination with daratumumab relapsed / refractory multiple myeloma. [ Time Frame: From start of treatment to end of treatment, up to 24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreMaryland21231-

Find similar trials in Baltimore, MD

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Baltimore, MD

Related Studies